MediPharm Labs Corp.
LABS.TO
TSX
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -4.54% | -2.61% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -4.54% | -2.61% | |||
| Cost of Revenue | -19.43% | 5.99% | |||
| Gross Profit | 47.52% | -24.13% | |||
| SG&A Expenses | -4.26% | -36.90% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 87.17% | 343.26% | |||
| Total Operating Expenses | -12.85% | -12.00% | |||
| Operating Income | 56.34% | 41.51% | |||
| Income Before Tax | 9.23% | 42.92% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 9.23% | 42.92% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 9.23% | 42.92% | |||
| EBIT | 56.34% | 41.51% | |||
| EBITDA | 67.76% | 46.67% | |||
| EPS Basic | 10.81% | 43.94% | |||
| Normalized Basic EPS | 56.52% | 43.90% | |||
| EPS Diluted | 10.81% | 43.94% | |||
| Normalized Diluted EPS | 56.52% | 43.90% | |||
| Average Basic Shares Outstanding | 0.23% | 1.30% | |||
| Average Diluted Shares Outstanding | 0.23% | 1.30% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||